MedTrace Logo

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

NCT05704361 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2026-08-13

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the safety and tolerability of a single-ascending intravenous (IV) dose (Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3), and multiple-ascending SC doses following a single IV dose (Part 4) of RO7121932 in participants with multiple sclerosis (MS). Only Parts 1 and 2 of the study will be conducted in the United States, whereas Parts 1, 2, 3, and 4 will be conducted in all other participating countries outside the United States.

Conditions

Interventions

DRUG

RO7121932 IV

Participants will receive RO7121932, as an IV infusion, per the schedule specified in the treatment arms.

DRUG

RO7121932 SC

Participants will receive RO7121932, as SC injection, per the schedule specified in the treatment arms.

Sponsors & Collaborators

Principal Investigators

  • Clinical Trials · Hoffmann-La Roche

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-11
Primary Completion
2027-07-08
Completion
2027-07-08
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Germany
  • Israel
  • Italy
  • Moldova
  • Poland
  • Portugal
  • Romania
  • Serbia
  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05704361 on ClinicalTrials.gov